Device Trial Radar · NCT05643235
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 1, 2023
Primary completion
Dec 1, 2027
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- Northwell HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.
Conditions
- Atrial Fibrillation
- Supraventricular Arrhythmia
- Ventricular Arrhythmias and Cardiac Arrest
- Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)Device
Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of device detected atrial fibrillation (AF)Time frame: at 18 months after start of BTK inhibitor
- Long term Incidence of device detected AFTime frame: up to 60 months after device implantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwell (Northshore University/Long Island Jewish Hospitals)
New Hyde Park, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.